Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Assembly Biosciences (ASMB) over the last 8 years, with Sep 2025 value amounting to $225,000.

  • Assembly Biosciences' Gains from Investment Securities was N/A to $225,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $225,000, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 19.49% down from last year.
  • Latest data reveals that Assembly Biosciences reported Gains from Investment Securities of $225,000 as of Q3 2025, which was down 0.00% from $225,000 recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Gains from Investment Securities ranged from a high of $2.8 million in Q4 2023 and a low of -$2.8 million during Q3 2021.
  • Its 3-year average for Gains from Investment Securities is $694,000, with a median of $225,000 in 2025.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 2,050.00% in 2022, then soared by 382.13% in 2023.
  • Over the past 5 years, Assembly Biosciences' Gains from Investment Securities (Quarterly) stood at -$219,000 in 2021, then crashed by 349.77% to -$985,000 in 2022, then skyrocketed by 382.13% to $2.8 million in 2023, then fell by 29.26% to $2.0 million in 2024, then reached $225,000 in 2025.
  • Its last three reported values are $225,000 in Q3 2025, $225,000 for Q2 2025, and $2.0 million during Q4 2024.